Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Yarrow Bioscience, Inc. (YARW) reported that venBio Global Strategic Fund V, L.P. and its general partner, venBio Global Strategic GP V, LLC, may each be deemed to beneficially own 1,211,820 common shares, approximately 9.99%, as of September 30, 2026. Fund V directly held 554,769 shares and 3,434,702 Pre-Funded Warrants; 657,051 shares acquirable within 60 days upon warrant exercise were included in the reported beneficial ownership.
Exercise is limited if it would cause the reporting entities and their affiliates, when aggregated, to own more than 9.99% immediately after exercise. The cap may be increased up to 19.99%, but any increase would not take effect until the 61st day after written notice is delivered to Yarrow Bioscience. The company had 11,473,285 common shares outstanding as of September 30, 2026.
Key Figures
Beneficial ownership:1,211,820 sharesCommon shares directly held:554,769 sharesShares acquirable through warrants:657,051 shares+4 more
7 metrics
Beneficial ownership1,211,820 sharesEach reporting entity may be deemed to own this amount as of September 30, 2026.
Common shares directly held554,769 sharesHeld directly by venBio Global Strategic Fund V, L.P.
Shares acquirable through warrants657,051 sharesAcquirable within 60 days upon exercise of Pre-Funded Warrants, subject to the Blocker.
Pre-Funded Warrants held3,434,702 warrantsHeld directly by venBio Global Strategic Fund V, L.P.
Beneficial ownership percentageApproximately 9.99%Each reporting entity's reported percentage as of September 30, 2026.
Common shares outstanding11,473,285 sharesOutstanding as of September 30, 2026.
Potential increased ownership capUp to 19.99%Any increase would not take effect until the 61st day after written notice is delivered to the issuer.
"shares Fund V has the right to acquire within 60 days upon exercise of Pre-Funded Warrants"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
Blockerfinancial
"subject to the Blocker"
beneficial ownershipregulatory
"may be deemed to beneficially own 1,211,820 shares"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Rule 13d-3(d)(1)(i)regulatory
"in accordance with Rule 13d-3(d)(1)(i) under the Exchange Act"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many YARW shares did venBio report beneficially owning?
Each of venBio Global Strategic Fund V, L.P. and its general partner, venBio Global Strategic GP V, LLC, may be deemed to beneficially own 1,211,820 shares, or approximately 9.99%, as of September 30, 2026. The entities report the same amount; these figures are not additive.
What is the YARW warrant ownership cap, and can it change?
The cap prevents warrant exercise to the extent it would cause the reporting entities and their affiliates, when required to aggregate ownership, to own more than 9.99% immediately after exercise. It may be increased up to 19.99%, with an increase effective on the 61st day after written notice is delivered to Yarrow Bioscience.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
Yarrow Bioscience, Inc.
(Name of Issuer)
Common Stock, $0.0001 par value
(Title of Class of Securities)
92941V407
(CUSIP Number)
09/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
92941V407
1
Names of Reporting Persons
venBio Global Strategic Fund V, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,211,820.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,211,820.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,211,820.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.99 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
92941V407
1
Names of Reporting Persons
venBio Global Strategic GP V, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,211,820.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,211,820.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,211,820.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.99 %
12
Type of Reporting Person (See Instructions)
HC, OO
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Yarrow Bioscience, Inc.
(b)
Address of issuer's principal executive offices:
470 James Street, Suite 007, New Haven, CT 06513
Item 2.
(a)
Name of person filing:
This Schedule 13G is being filed by the following persons (each a "Reporting Person" and together the "Reporting Persons"):
i. venBio Global Strategic Fund V, L.P. ("Fund V"); and
ii. venBio Global Strategic GP V, LLC ("General Partner V").
Each of Aaron Royston ("Dr. Royston"), Corey Goodman ("Dr. Goodman"), and Richard Gaster ("Dr. Gaster") is a member of General Partner V but, in reliance on the "rule of three," disclaims beneficial ownership over the shares of Common Stock reported herein as beneficially owned by the Reporting Persons.
(b)
Address or principal business office or, if none, residence:
The principal business address of each Reporting Person is 1700 Owens Street, Suite 595, San Francisco, CA 94158.
(c)
Citizenship:
i. Fund V is a Delaware partnership; and
ii. General Partner V is a Delaware limited liability company.
(d)
Title of class of securities:
Common Stock, $0.0001 par value
(e)
CUSIP No.:
92941V407
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
As of September 30, 2026, each Reporting Person may be deemed to beneficially own 1,211,820 shares of Common Stock. This amount consists of (i) 554,769 shares of Common Stock directly held by Fund V and (ii) 657,051 shares of Common Stock that Fund V has the right to acquire within 60 days upon the exercise of Pre-Funded Warrants, subject to the Blocker.
Fund V directly holds 3,434,702 Pre-Funded Warrants. However, pursuant to the terms of the Pre-Funded Warrants, Fund V shall not have the right to exercise any portion of the Pre-Funded Warrants to the extent that any such exercise would result in the Reporting Persons and their affiliates, if acting as a group and required to aggregate their beneficial ownership of Common Stock pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), owning more than 9.99% of the issued and outstanding shares of Common Stock immediately after giving effect to such exercise, subject to a potential increase up to a 19.99% cap provided that any increase will not be effective until the 61st day after written notice of such increase is delivered to the Issuer (the "Blocker").
(b)
Percent of class:
As of September 30, 2026, each Reporting Person may be deemed to beneficially own approximately 9.99% of the shares of Common Stock outstanding.
The amount and percent of class beneficially owned as of September 30, 2026, is based on (i) 11,473,285 shares of Common Stock outstanding as of September 30, 2026, as reported in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 13, 2026, and (ii) 657,051 shares of Common Stock that Fund V has the right to acquire within 60 days upon the exercise of Pre-Funded Warrants, subject to the Blocker, which shares are added to the total shares of Common Stock outstanding for purposes of calculating the Reporting Persons' beneficial ownership percentage in accordance with Rule 13d-3(d)(1)(i) under the Exchange Act.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
0
(ii) Shared power to vote or to direct the vote:
1,211,820
(iii) Sole power to dispose or to direct the disposition of:
0
(iv) Shared power to dispose or to direct the disposition of:
1,211,820
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
See disclosure in Item 2 hereof.
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
venBio Global Strategic Fund V, L.P.
Signature:
/s/ David Pezeshki
Name/Title:
David Pezeshki, as attorney-in-fact for Aaron Royston, Corey Goodman, and Richard Gaster, Members of the General Partner
Date:
11/16/2026
venBio Global Strategic GP V, LLC
Signature:
/s/ David Pezeshki
Name/Title:
David Pezeshki, as attorney-in-fact for Aaron Royston, Corey Goodman, and Richard Gaster, Members
Date:
11/16/2026
Comments accompanying signature: This Schedule 13G was executed by David Pezeshki on behalf of the individuals listed above pursuant to a Power of Attorney, copies of which are attached as Exhibit 2 and Exhibit 3 to the Schedule 13G.
Exhibit Information
Exhibit 1: Joint Filing Agreement
Exhibit 2: Power of Attorney regarding filings under the Exchange Act
Exhibit 3: Power of Attorney regarding filings under the Exchange Act